Tümör Biyobelirteçleri: Enzimler
Özet
Bu derlemede, enzimlerin tümör tanısı, tedavisi, prognozu ve nüks takibindeki rolleri ile klinik önemleri ayrıntılı olarak incelenmektedir. Tümör hücrelerinin sağlıklı dokulardan farklı protein ve enzim bütünlüğüne sahip olması, enzimatik değişimleri hastalıklara özgü değerli biyobelirteçler kılmaktadır. Metinde öne çıkan temel tümör ilişkili enzimler arasında; prostat karsinomunda tarama, tanı ve takipte kullanılan Prostat Spesifik Antijen (PSA), metastatik prostat kanserinde ve immünoterapi hedeflerinde rol oynayan Prostatik Asit Fosfataz (PAF) ve akut miyeloid ile monositik lösemilerde yükselen Lizozim yer almaktadır. Bunun yanı sıra, küçük hücreli akciğer kanseri ve nöroblastomada evreleme ile prognozu değerlendirmede yararlanılan Nöron Spesifik Enolaz (NSE) ve primer veya sekonder karaciğer tümörleri ile kemik metastazlarında artış gösteren Alkalen Fosfataz (ALP) detaylandırılmıştır. Ayrıca doku yeniden şekillenmesinde görev alan Matriks Metaloproteinazlar (MMP), anjiyogenez proteini Anjiyogenin, lösemide önemli bir prognostik parametre olan Timidin Kinaz, hücre siklüsü ve apoptoz süreçlerinde rol oynayan CK-BB, Siklin Bağımlı Kinaz 6, Kaspaz 3 ve Pepsinojen 1 ile hepatoselüler karsinomada aktivitesi azalan Tripsin gibi çeşitli enzimlerin tümör dokularındaki farklılaşmaları ele alınmıştır. Sonuç olarak, enzimatik biyobelirteçler kanser yönetiminde kritik araçlar sunmakla birlikte, mevcut testlerin göreceli duyarlılık ve özgüllük eksikliği nedeniyle ideal tek bir belirteç bulunmamakta ve ileri araştırmalara ihtiyaç duyulmaktadır.
Referanslar
Wang M, Valenzuela L, Murphy G, et al. Purification of a human prostate specific antigen. Invest Urol, 1979; 17 (2), 159-163.
Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med, 1991; 324 (17), 1156-1161.
Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 1987; 317 (15), 909-916.
Taira A, Merrick G, Wallner K, et al. Reviving the acid phosphatase test for prostate cancer. Oncology (Williston Park), 2007; 21 (8), 1003-1010.
Babu GS, Supriya AN, Kumar NGR, et al. Tumor markers: An overview. J Orofac Sci, 2012; 4 (2), 87.
Malati T. Tumour markers: An overview. Indian J Clin Biochem, 2007; 22 (2), 17-31.
Afzal S, Ahmad M, Mushtaq S, et al. Morphological features correlation with serum tumour markers in prostatic carcinoma. J Coll Physicians Surg Pak, 2003; 13 (9), 511-514.
Potluri HK, Ng TL, Newton MA, et al. Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages. J Immunother Cancer, 2020; 8 (2).
Keshav S, Chung P, Milon G, et al. Lysozyme is an inducible marker of macrophage activation in murine tissues as demonstrated by in situ hybridization. J Exp Med, 1991; 174 (5), 1049-1058.
Osserman EF, Lawlor DP. Serum and urinary lysozyme (muramidase) in monocytic and monomyelocytic leukemia. J Exp Med, 1966; 124 (5), 921-952.
Bancroft J, Marilyn G. (2002). Immunohistochemistry and diagnostic pathology. Theory and Practice of Histological Techniques. (5th edition) NY: Elsevier.
Shaikh NA, Memon F, Samro RP. Tumor Markers. T Pro Med J, 2014; 21 (04), 621-627.
Burtis CA, Bruns DE. (2014). Tietz fundamentals of clinical chemistry and molecular diagnostics. (7th edition) NY: Elsevier Health Sciences.
Neuschwander-Tetri BA. Common blood tests for liver disease. Which ones are most useful? Postgrad Med, 1995; 98 (1), 49-56.
Maldonado O, Demasi R, Maldonado Y, et al. Extremely high levels of alkaline phosphatase in hospitalized patients. J Clin Gastroenterol, 1998; 27 (4), 342-345.
Fishman WH, Inglis NI, Stolbach LL, et al. A serum alkaline phosphatase isoenzyme of human neoplastic cell origin. Cancer Res, 1968; 28 (1), 150-154.
Fishman WH, Inglis NR, Green S, et al. Immunology and biochemistry of Regan isoenzyme of alkaline phosphatase in human cancer. Nature, 1968; 219 (5155), 697-699.
Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer, 2004; 111 (5), 783-791.
Diamandis EP. (2002). Tumor markers: physiology, pathobiology, technology, and clinical applications. (1st edition) NY: Amer. Assoc. for Clinical Chemistry
Niewczas M, Paczek L, Krawczyk M, et al. Enzymatic activity of cathepsin B, cathepsin B and L, plasmin, trypsin and collagenase in hepatocellular carcinoma. Pol Arch Med Wewn, 2002; 108 (1), 653-662.
Peltonen R, Hagstrom J, Tervahartiala T, et al. High Expression of MMP-9 in Primary Tumors and High Preoperative MPO in Serum Predict Improved Prognosis in Colorectal Cancer with Operable Liver Metastases. Oncology, 2020; 1-17.
Kuropkat C, Plehn S, Herz U, et al. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer. Anticancer Res, 2002; 22 (4), 2221-2227.
Liutkevicius V, Lesauskaite V, Liutkeviciene R, et al. Matrix Metalloproteinases (MMP-2,-3,-9) Gene Polymorphisms in Cases of Benign Vocal Fold Lesions and Laryngeal Carcinoma. In Vivo, 2020; 34 (1), 267-274.
Pavlov N, Badet J. Angiogenin: involvement in angiogenesis and tumour growth. Bull Cancer, 2001; 88 (8), 725-732.
Lucas JJ, Domenico J, Gelfand EW. Cyclin-dependent kinase 6 inhibits proliferation of human mammary epithelial cells. Mol Cancer Res, 2004; 2 (2), 105-114.
Konturek SJ, Konturek PC, Bielanski W, et al. Serum progastrin and its products, gastric acid secretion and serum pepsinogen I in gastric cancer. Digestion, 2003; 68 (4), 169-177.
Akcay MN, Polat MF, Yilmaz I, et al. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology, 2003; 50
Akcay MN, Yilmaz I, Polat MF, et al. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology, 2003; 50
Soderberg A, Sahaf B, Rosen A. Thioredoxin reductase, a redox-active selenoprotein, is secreted by normal and neoplastic cells: presence in human plasma. Cancer Res, 2000; 60 (8), 2281-2289.
Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma, 1996; 22 (5-6), 439-447.
Sun H, Zheng H, Yang X, et al. Expression of PTEN and Caspase-3 and their clinicopathological significance in primary gastric malignant lymphoma. Chin Med Sci J, 2004; 19 (1), 19-24.
Silverman LM, Dermer GB, Zweig MH, et al. Creatine kinase BB: a new tumor-associated marker. Clin Chem, 1979; 25 (8), 1432-1435.
